Francesco Sclafani

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

Andrew Woolston, Khurum Khan, Georgia Spain et al. · Cancer Cell · 2019 · 254 citations · Full text

Tumor Biology, Cetuximab Resistance Landscape, Immune Landscape Evolution +13

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma

Nicola Personeni, Silvia Bozzarelli, Tiziana Pressiani et al. · Journal of Hepatology · 2012 · 206 citations

Hepatology, Hepatocellular Carcinoma, Medicine +8

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

Francesco Sclafani, Gina Brown, David Cunningham et al. · British Journal of Cancer · 2017 · 178 citations · Full text

International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct

Sheela Rao, Francesco Sclafani, Cathy Eng et al. · Journal of Clinical Oncology · 2020 · 140 citations · Full text

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,<i>KRAS</i>Wild-Type, Metastatic Colorectal Cancer

Francesco Sclafani, Tae‐Yop Kim, David Cunningham et al. · JNCI Journal of the National Cancer Institute · 2015 · 88 citations · Full text